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The World Health Organization (WHO) estimates that in 2016, 
10.4 million people were infected with tuberculosis (TB) globally, 
including 1.2 million who were HIV co-infected.[1] Of these, 63% 
were notified in TB programmes, reflecting a gap in detection of cases 
and access to care.[1] In 2014, globally 490 000 people had multidrug-
resistant (MDR)-TB (defined as resistance to both rifampicin and 
isoniazid), with an additional 100 000 rifampicin-monoresistant 
cases requiring second-line medication.[2] South Africa (SA) faces 
a huge burden of TB (including MDR-TB) and HIV co-infection. 
The incidence of TB in 2014 was 834 per 100 000, the TB/HIV 
co-infection rate was 57%, and 18  734 rifampicin-resistant cases 
were laboratory confirmed. In total, 11 538 patients with rifampicin-
resistant/MDR-TB were reported to have been started on MDR-TB 
treatment in SA in the year 2014, reflecting a gap in drug-resistant 
(DR) TB treatment.[3] Furthermore, many persons with undiagnosed 
TB were reported to have died from other causes in settings with a 
high TB burden.[4]
Mortality rates of 71% have been reported in HIV-co-infected 
MDR-TB patients in KwaZulu-Natal (KZN) Province, SA. [5] Histori-
cally, TB has been diagnosed through sputum smear microscopy 
examina tion and conventional sputum culture with or without a 
chest radiograph. Unfortunately, drawbacks of this method include 
a low sensitivity of smear microscopy in TB/HIV co-infection and 
a long turnaround time for culture. Long turnaround time leads to 
inappropriate treatment of MDR-TB patients, with a possible increase 
of resistance and continued spread of resistant mycobacteria. [6-8] In 
2013, the WHO recommended use of Xpert MTB/RIF assay as the 
initial diagnostic test in presumptive MDR-TB cases and in TB/
HIV co-infection.[7] Xpert MTB/RIF (Xpert) (Cepheid, USA) assay 
is a fully automated cartridge-based nucleic acid amplification test. 
A meta-analysis of laboratory and demonstration studies found a 
pooled sensitivity of 89% and specificity of 99%, although sensitivity 
in high HIV prevalence settings is lower, at 79%.[9] Between 2011 and 
2013, the SA National Department of Health rolled out Xpert assays 
as an initial diagnostic test for all presumptive TB cases to all health 
districts in the country.[10]
Prior to Xpert use, the MDR-TB treatment success rate was 58% 
in KZN,[11] which is below the 85% target set by the WHO’s End TB 
strategy.[12] Studies have reported variable TB treatment outcomes 
with Xpert. A randomised trial in SA on the effect of replacing 
microscopy with Xpert found no difference in 6-month mortality in 
drug-susceptible TB cases.[13]
Few studies have addressed the effect of Xpert on MDR-TB patients. 
One study in SA that compared MDR-TB treatment commencement 
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times in line probe assay and Xpert-based algorithms showed a 
median reduction of 25 days in time to commencement of MDR-TB 
treatment for patients diagnosed using the Xpert-based algorithm. [2,6] 
However, the benefit of earlier diagnosis and commencement of 
appropriate treatment on treatment outcomes is unknown.
Objectives
The primary objective of the study was to assess whether the use of 
Xpert as the initial TB diagnostic assay improved MDR-TB treatment 
outcomes compared with smear/culture/drug-sensitive tests (DSTs) 
in Ugu Health District, KZN. We hypothesised that the use of Xpert 
as the primary test in presumptive TB cases would lead to earlier 
MDR-TB initiation and consequently better clinical outcomes. Our 
secondary objective was to compare the time to MDR-TB treatment 
initiation for cases diagnosed by the two methods.
Methods
Setting
The study was undertaken in the Murchison District Hospital DR-TB 
unit, which serves as the referral centre for all DR-TB patients in Ugu 
Health District. Ugu Health District had a population of 750 000 
people and an HIV prevalence rate of 17% in 2012.[14] All rifampicin-
resistant and DR-TB patients diagnosed in the district are referred 
to this unit for DR-TB treatment. The Xpert-based algorithm was 
phased into the facilities between 2012 and 2013, with variable 
compliance with the algorithm on the part of clinicians.
Study design
We retrospectively reviewed medical records of patients with 
rifampicin-monoresistant and MDR pulmonary TB diagnosed and 
initiated on MDR-TB treatment between January 2012 and April 
2014. Cohorts were defined by the initial diagnostic assay used in 
testing the presumptive TB case. In the Xpert cohort, the initial 
diagnostic assay was Xpert. In the smear/culture cohort, the initial 
diagnostic assay was either smear or culture and DST was via 
conventional DSTs or the GenoType MTBDRplus (Hain LifeScience 
GmbH, Germany) line probe assay.
The primary measure of treatment outcome was assessed after 
a minimum 2-year follow-up period for patients completing 24 
months of follow-up or at the clinical endpoint reported for those not 
completing 24 months of treatment.
Study population
Inclusion criteria. Patients aged >15 years with confirmed pulmon-
ary MDR-TB and rifampicin-monoresistant patients recorded in the 
DR-TB register at Murchison District Hospital between January 2012 
and June 2014 were included in the study.
Exclusion criteria. Patients with monoresistance (other than 
rifampicin monoresistance), polyresistant TB and extensively drug-
resistant (XDR)-TB and participants <15 years of age (as they are 
usually not treated at this facility) were excluded from the study.
Treatment outcome definitions
National Department of Health drug-resistant tuberculosis direc-
torate policy guidelines were used, as the study was a pragmatic 
examination of the impact of an intervention at a programme 
level. [10]
Cure. A patient with pulmonary TB, with bacteriologically 
confirmed TB at the start of treatment, who has completed treatment 
and has converted to smear/culture-negative (with two consecutive 
negative TB cultures taken 30 days apart). If one positive culture 
is reported during that time and there is no concomitant clinical 
evidence of deterioration, a patient may still be considered cured if 
this positive culture is followed by a minimum of three consecutive 
negative cultures, taken at least 30 days apart.
Treatment completed. A patient who has completed treatment but 
does not meet the definition for cure owing to lack of bacteriological 
results (i.e. fewer than three cultures were negative after TB culture 
conversion).
Death. A patient who dies from any cause while on DR-TB 
treatment.
Treatment default. A patient who interrupts DR-TB treatment for 
2 or more consecutive months for any reason.
Treatment failure. Treatment is considered to have failed when 
two or more of the five consecutive cultures taken in the final 
12  months are positive, or if any one of the final three cultures is 
positive. Treatment failure may be observed in patients who do not 
respond to treatment after 6 - 8 months of effective treatment. Such 
patients will be put on a different treatment regimen after receiving 
an outcome of failure and will be allocated to a new treatment cohort.
Transfer out. A patient who has been transferred to a reporting 
unit in another province and for whom the treatment outcome is 
unknown.
Ethical considerations
The Stellenbosch University Human Research Ethics Committee 
(ref. no. S16/04/079) and the Provincial Health Research and Ethics 
Committee of KwaZulu-Natal (ref. no. KZ-2016RP32-836) approved 
the study. De-identified routine medical data were used in the study. 
Informed consent was waived by the ethics committees because 
the study used routinely collected historical data and had no direct 
contact with patients.
Statistical analysis
We assumed treatment success rates of 50% in the smear/culture 
cohort and 60% in the Xpert cohort, based on previous studies. [15] 
With a power of 80% and two-sided alpha of 0.05, we required 
776 participants.
Demographic characteristics and treatment outcomes were 
compared using the χ2 test or Fisher’s exact test. We compared the 
cumulative probabilities of starting treatment between the Xpert 
cohort and the smear/culture cohort using Kaplan-Meier estimation 
methods and the log-rank test. Logistic regression analysis was used 
to test the influence of covariates on treatment success. Stata 14 
(StataCorp, USA) was used for analysis.
Results
Of a total of 820 MDR-TB cases screened, 718 met the study inclusion 
criteria (Fig. 1). One hundred and two patients were excluded: 
1 was a duplicate entry, 93 had polyresistant TB (not including 
both isoniazid and rifampicin) and monoresistant TB (excluding 
rifampicin monoresistance), and 8 were aged <15 years. We enrolled 
354 patients into the smear/culture cohort and 364 into the Xpert 
cohort.
Demographic and clinical characteristics of the  
study patients
There were no significant differences between the two groups in 
terms of gender, age or referral facility (Table 1). The smear/culture 
cohort had a higher proportion of patients with previously treated 
TB (p<0.01). In the smear/culture cohort, 272 of 354 patients (76.3%) 
and in the Xpert cohort 271 of 345 (78.6%) were HIV-positive.
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MDR-TB treatment outcomes
In the smear/culture cohort, 158 of 354 patients (43.5%) were cured 
compared with 118 of 364 (33.5%) in the Xpert cohort (p=0.02).
Treatment was completed in 27 of 354 patients (8.6%) in the 
smear/culture cohort compared with 41 of 364 (11.7%) in the Xpert 
cohort (p=0.68).
In the smear/culture cohort 82 patients (22.5%) were lost to 
follow-up, compared with 100 (28.4%) in the Xpert cohort (p<0.01) 
(Table 2).
Predictors of cure outcome
In multivariable logistic binominal regression analysis, Xpert 
diagnosis (adjusted risk ratio (aRR) 0.65; p=0.02) and male gender 
(aRR 0.66; p=0.04) were associated with cure outcome (Table  3). 
Xpert increased time to sputum culture conversion from 4 to 
5 months (log-rank test p=0.01).
Time to treatment initiation was not associated with treatment 
success in either univariate or multivariate analysis.
Median time to MDR-TB treatment initiation
Median time to MDR-TB treatment initiation was 62 days 
(interquartile range (IQR) 56 - 67) in the smear/culture cohort 
compared with 11 days (IQR 9 - 12) in the Xpert cohort (log-rank 
test p<0.01) (Fig. 2).
Discussion
This study compared clinical outcomes between patients diagnosed 
by smear/culture and those diagnosed by Xpert at the point at which 
they were presumptive TB cases. The study demonstrated lack of 
improvement in treatment outcomes in the Xpert cohort, despite a 
significant reduction in time to treatment initiation in this group. 
Theoretically, cases diagnosed by Xpert would be diagnosed earlier 
in their disease progression, and we expected to find improved 
outcomes. Although treatment delay was not a significant factor for 
treatment success in the multivariable regression analysis, it should Cases identied from DR-TB register
N=820
Eligible pulmonary MDR- or 
rifampicin-resistant TB patients
n=726
Included in study
n=718
Xpert cohort
n=364
Smear/culture cohort
n=354
Excluded: polyresistant TB 
(or monoresistant TB excluding 
rifampicin monoresistance)
n=93
Excluded: duplicate entry
n=1
Excluded: age <15 years
n=8
Fig. 1. Cases included in and excluded from the study. (DR = drug-resistant; 
TB = tuberculosis, MDR = multidrug-resistant.)
Table 1. Demographic and clinical characteristics of study patients
Characteristics Smear/culture cohort (N=354) Xpert cohort (N=364) p-value
Female gender, n (%) 185 (52.3) 176 (48.3) 0.28
Age (years), mean (SD) 34.8 (11.4) 35.0 (10.5) 0.83
HIV-positive,* n (%) 271 (76.3) 272 (78.2) 0.53
TB treatment, n (%) <0.01
New cases 155 (43.8) 238 (65.3)
Previous first-line TB medication† 142 (40.1) 112 (30.8)
Previous second-line TB medication 43 (12.2) 13 (3.7)
ARV history, n (%) 0.06
On ARVs before treatment started‡ 171 (63.0) 144 (52.8)
Started ARVs while on treatment 84 (31.3) 106 (39.0
Never started ARVs 15 (5.7) 29 (8.2)
Referral facility, n (%) 0.20
From primary healthcare§ 137 (38.8 117 (32.3)
From district hospital 33 (9.3) 43 (11.9)
From community health clinic 170 (47.9) 172 (47.2)
From private institutions 14 (3.9) 6 (1.7)
SD = standard deviation; TB = tuberculosis; ARV = antiretroviral.
*9 participants in the smear/culture cohort and 6 in the Xpert cohort refused to be tested for HIV, or the result was not indicated.
†2 participants in the smear/culture cohort had missing information on previous drug treatment history.
‡2 participants in smear/culture cohort and 8 in the Xpert cohort had missing ARV treatment history.
§9 participants in the smear/culture cohort and 6 in the Xpert cohort had missing information on previous treatment history.
 
Figure 2 Comparison of time to MDR-TB treatment i iti tion in the Xpert an culture 
cohorts. Log rank test (p<0.01) 
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Fig. 2. Comparison of time to MDR-TB treatment initiation in the Xpert 
and culture cohorts. Log-rank test, p<0.01. (MDR-TB = multidrug-resistant 
tuberculosis.)
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be noted that we assessed delay only from the time of the first TB test 
and not from TB symptom onset.
Clinicians chose which assay to use and may have used Xpert on 
sicker patients, introducing a selection bias that contributed to the 
lower treatment success rates. It is possible that Xpert assay identified 
a higher proportion of sicker patients because of its improved 
sensitivity compared with smear, resulting in the poorer outcomes.
Our study findings were similar to previous studies showing that 
Xpert assay reduced time to MDR-TB treatment initiation.[16-19] 
However, early treatment initiation was not associated with treatment 
success, which may explain the lack of improvement in clinical 
outcomes. Our study agrees with recent studies demonstrating that 
use of Xpert has not reduced early mortality in rifampicin-resistant 
patients.[20]
Our study demonstrated poorer outcomes for men than for 
women, echoing findings from previous studies.[21,22]
Previous studies have shown that early initiation of antiretrovirals 
(ARVs) reduces mortality attributed to TB in HIV co-infected 
patients.[22,23] Almost half of our patients in the Xpert cohort who 
were HIV-positive were not on ARV treatment when they were 
initiated on MDR-TB treatment, compared with 63.0% in the smear/
culture cohort (p=0.06). However, we were surprised to find that 
ARV treatment was not significantly associated with treatment 
success after adjusting for other factors.
Study strengths and limitations
Strengths of this study were a large sample size and the fact that 
we included all eligible subjects initiated on MDR-TB treatment 
in the district during the study period. The study is a pragmatic 
examination of the impact of an intervention on important clinical 
endpoints.
Limitations include the retrospective nature of the study using 
routinely collected data, with some data entries missing. We were 
unable to control for possible confounders (baseline lung damage, 
CD4+ counts, body mass index), as the TB register lacked this clinical 
information. Our study did not look at initial loss to follow-up in 
presumptive DR-TB patients, as we only studied those who were 
diagnosed and entered into care at the DR-TB unit.
For missing outcomes, the primary investigator inferred the 
outcome from the latest available information in the register using 
SA national DR-TB guidelines outcome definitions.[10] Patients with 
missing results were excluded from sub-analysis involving those 
missing variables, possibly introducing bias.
Implications of the study findings
Xpert led to early initiation of MDR-TB treatment, which may help 
reduce further DR-TB transmission.[24] A recently published study 
conducted in KZN demonstrated that 69% of XDR-TB patients had 
never received MDR-TB treatment, and the XDR-TB was probably 
due to transmission and not inadequate treatment. The authors 
concluded that there was a need to interrupt DR-TB transmission.[25]
There is a need for interventions targeting men, as they had poorer 
treatment outcomes than women. However, treatment success rates 
remain very low in both genders, coupled with high loss to follow-up 
and mortality.[26] There is a need for further research to determine 
possible factors associated with treatment success.
Table 3. Predictors of cure outcome
Predictor variable Univariate RR (95% CI) p-value Multivariate aRR (95% CI) p-value
Smear/culture diagnosis Reference
Xpert diagnosis 0.68 (0.53 - 0.87) <0.01 0.65 (0.45 - 0.93) 0.02
Age 1.00 (0.99 - 1.02) 0.44 1.01 (0.99 - 1.02) 0.11
Female Reference
Male gender 0.76 (0.59 - 0.98) 0.04 0.66 (0.45 - 0.97) 0.04
Referred from hospital Reference
Referred from community health centre 0.92 (0.58 - 1.48) 0.76 1.14 (0.65 - 2.08) 0.67
Referred from primary healthcare clinic 1.18 (0.89 - 1.55) 0.25 1.19 (0.70 - 1.80) 0.55
Referred from private health institution 1.07 (0.55 - 2.08) 0.85 1.30 (0.55 - 3.04) 0.55
TB drug treatment naive Reference
Previous first-line TB drug treatment history 1.04 (0.81 - 1.35) 0.74 1.23 (0.85 - 1.77) 0.27
HIV-negative Reference
On ARVs when MDR-TB treatment started 0.86 (0.61 - 1.14) 0.29 1.11 (0.78 - 1.59) 0.55
RR = risk ratio; aRR= adjusted risk ratio; CI = confidence interval; TB = tuberculosis; ARVs = antiretrovirals; MDR = multidrug-resistant.
Table 2. Comparison of drug-resistant tuberculosis treatment outcomes for the smear/culture and Xpert cohorts
Outcome 
Smear/culture cohort 
(N=354), n (%)
Xpert cohort (N=364), 
n (%)
Univariate RR  
(95% CI) p- value
Multivariate aRR  
(95% CI) p-value
Cured 158 (43.4) 118 (33.5) 0.68 (0.53 - 0.87) <0.01 0.65 (0.45 - 0.92)* 0.02
Treatment completed 27 (8.6) 41 (11.7) 1.01 (0.60 - 1.70) 0.98 0.28 (0.09 - 0.89) 0.03
Lost to follow-up 82 (22.5) 100 (28.4) 1.61 (1.14 - 2.28) <0.01 †
Died 50 (13.7) 61 (16.8) 1.08 (0.68 - 1.73) 0.73 1.05 (0.58 - 1.9) 0.88
Treatment failure 35 (9.6) 29 (8.2) 1.09 (0.50 - 2.38) 0.82 0.89 (0.34 - 3.38) 0.87
Transferred out 2 (0.6) 3 (0.9)
RR = risk ratio; aRR= adjusted risk ratio; CI = confidence interval.
*Multivariate binominal log regression failed to converge when time to treatment initiation was added to the iteration because of complexity of the model.
†Multivariate log regression failed to converge. Loss to follow-up described is only for patients who were lost to follow-up after being started on tuberculosis treatment and did not include initial 
loss to follow-up before treatment was started.
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Conclusions
Despite rapid treatment initiation, MDR-TB treatment outcomes 
were poorer in patients diagnosed with Xpert MTB/RIF assay than in 
the smear/culture cohort, and they were also poorer in men than in 
women. Additional pragmatic studies are required to assess possible 
factors influencing MDR-TB treatment outcomes.
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